1. Home
  2. CHRS vs ALCO Comparison

CHRS vs ALCO Comparison

Compare CHRS & ALCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • ALCO
  • Stock Information
  • Founded
  • CHRS 2010
  • ALCO 1960
  • Country
  • CHRS United States
  • ALCO United States
  • Employees
  • CHRS N/A
  • ALCO N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • ALCO
  • Sector
  • CHRS Health Care
  • ALCO
  • Exchange
  • CHRS Nasdaq
  • ALCO Nasdaq
  • Market Cap
  • CHRS 191.3M
  • ALCO 186.1M
  • IPO Year
  • CHRS 2014
  • ALCO N/A
  • Fundamental
  • Price
  • CHRS $1.43
  • ALCO $32.31
  • Analyst Decision
  • CHRS Strong Buy
  • ALCO
  • Analyst Count
  • CHRS 4
  • ALCO 0
  • Target Price
  • CHRS $5.38
  • ALCO N/A
  • AVG Volume (30 Days)
  • CHRS 2.3M
  • ALCO 92.9K
  • Earning Date
  • CHRS 11-06-2024
  • ALCO 02-05-2025
  • Dividend Yield
  • CHRS N/A
  • ALCO 0.66%
  • EPS Growth
  • CHRS N/A
  • ALCO 279.17
  • EPS
  • CHRS N/A
  • ALCO 0.91
  • Revenue
  • CHRS $304,340,000.00
  • ALCO $46,643,000.00
  • Revenue This Year
  • CHRS $2.47
  • ALCO $91.35
  • Revenue Next Year
  • CHRS N/A
  • ALCO N/A
  • P/E Ratio
  • CHRS N/A
  • ALCO $33.35
  • Revenue Growth
  • CHRS 44.19
  • ALCO 17.06
  • 52 Week Low
  • CHRS $0.66
  • ALCO $24.14
  • 52 Week High
  • CHRS $2.97
  • ALCO $34.08
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 49.74
  • ALCO 70.60
  • Support Level
  • CHRS $1.44
  • ALCO $28.58
  • Resistance Level
  • CHRS $1.60
  • ALCO $34.08
  • Average True Range (ATR)
  • CHRS 0.12
  • ALCO 1.41
  • MACD
  • CHRS -0.02
  • ALCO 0.46
  • Stochastic Oscillator
  • CHRS 25.00
  • ALCO 79.72

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About ALCO Alico Inc.

Alico Inc is a Florida-based agribusiness and land management company that primarily focuses on citrus production and grove conservation. The company operates through two primary business units: Alico Citrus and Land Management and Other Operations. The Alico Citrus segment engages in cultivation of citrus trees and delivers citrus to the processed and fresh citrus markets. It mainly serves the processed market and sells primarily Hamlin oranges and the Valencia variety to the orange juice processors. The Land Management and Other Operations segment engages in land leasing for recreational, conservation, and mining activities. Alico Citrus delivers most of the revenue as the firm's primary operating business unit.

Share on Social Networks: